Effect of body weight loss and normalization on blood pressure in overweight non-obese patients with stage 1 hypertension

Aims. To study of the polymorphisms of the TPN2 and GNB3 genes in obese patients and their effect on weight loss in patients on sibutramine therapy. Materials and methods. The research study included 118 patients with exogenous-constitutional obesity who received Reduxin (sibutramine + CMC) at the dose of 10 mg. Term follow-up was 3 months. A genetic study was performed to assess ТРН2 and GNB3 gene polymorphisms. The response to the therapy was evaluated after 3 months by the dynamics of body weight. Results. In the study the G703T polymorphism of the GNB3 gene showed that during 3 months of observation, carriers of the TT genotype had a greater decrease in body weight in comparison with carriers of the allele C -8 kg (-12; -5) vs. -5 kg (-8; -3), p = 0.018. In carriers of different variants of the genotype of the TPH2 gene (polymorphism C825T), there was no difference in body weight dynamics with sibutramine therapy. There was no correlation between the foresaid polymorphisms of the TPH2 and GNB3 genes with the indices of blood pressure and heart rate. Conclusions. 1. The result of sibutramin therapy may depend on genetic factors: in carriers of the TT-genotype C825T of the GNB3 gene the body weight loss was higher than among the carriers of the C allele. 2. Changes in blood pressure and heart rate did not show any statistically significant relationship with polymorphisms of the TPH2 and GNB3 genes.

Download Full-text

QS83. Muscle Loss Constitutes A Significant Component of Body Weight Loss in Morbidly Obese Patients Following Laparoscopic Roux-en-Y Gastric Bypass (LRYGB)

Journal of Surgical Research ◽

10.1016/j.jss.2007.12.323 ◽

2008 ◽

Vol 144 (2) ◽

pp. 301-302

Author(s):

Aaron W. Eckhauser ◽

Homaira Ayesha Hossain ◽

Pamela A. Marks ◽

James M. Isbell ◽

Philip E. Williams ◽

...

Keyword(s):

Weight Loss ◽

Gastric Bypass ◽

Body Weight ◽

Body Weight Loss ◽

Morbidly Obese ◽

Obese Patients ◽

Muscle Loss ◽

Significant Component

Download Full-text

The influence of body weight loss on gait and stability functioning in obese patients

Annals of Physical and Rehabilitation Medicine ◽

10.1016/j.rehab.2018.05.682 ◽

2018 ◽

Vol 61 ◽

pp. e292

Author(s):

L. Marchenkova ◽

V. Valeria ◽

M. Eryomushkin

Keyword(s):

Weight Loss ◽

Body Weight ◽

Body Weight Loss ◽

Obese Patients

Download Full-text

H48 Factors predicting blood pressure response to body weight loss ? the harvest study

American Journal of Hypertension ◽

10.1016/s0895-7061(97)88969-8 ◽

1997 ◽

Vol 10 (4) ◽

pp. 88A

Author(s):

M WINNICKI

Keyword(s):

Blood Pressure ◽

Weight Loss ◽

Body Weight ◽

Blood Pressure Response ◽

Body Weight Loss ◽

Pressure Response

Download Full-text

Therapy of obesity by sibutramin: polymorphisms of TPH2 and GNB3 genes and decrease of body weight

Obesity and metabolism ◽

10.14341/omet2018240-45 ◽

2018 ◽

Vol 15 (2) ◽

pp. 40-45

Author(s):

Marina O Galieva ◽

Ekaterina A Troshina ◽

Nataliya V Mazurina ◽

Anna P Volynkina ◽

Andrey Artiushin ◽

...

Keyword(s):

Blood Pressure ◽

Heart Rate ◽

Weight Loss ◽

Body Weight ◽

Genetic Factors ◽

Research Study ◽

Body Weight Loss ◽

The Body ◽

Tph2 Gene

AIMS. To study of the polymorphisms of the TPN2 and GNB3 genes in obese patients and their effect on weight loss in patients on sibutramine therapy. MATERIALS AND METHODS. The research study included 118 patients with exogenous-constitutional obesity who received Reduxin (sibutramine + CMC) at the dose of 10 mg. Term follow-up was 3 months. A genetic study was performed to assess ТРН2 and GNB3 gene polymorphisms. The response to the therapy was evaluated after 3 months by the dynamics of body weight. RESULTS. In the study the G703T polymorphism of the GNB3 gene showed that during 3 months of observation, carriers of the TT genotype had a greater decrease in body weight in comparison with carriers of the allele C – -8 kg (-12; -5) vs. -5 kg (-8; -3), p = 0.018. In carriers of different variants of the genotype of the TPH2 gene (polymorphism C825T), there was no difference in body weight dynamics with sibutramine therapy. There was no correlation between the foresaid polymorphisms of the TPH2 and GNB3 genes with the indices of blood pressure and heart rate. CONCLUSIONS. 1. The result of sibutramin therapy may depend on genetic factors: in carriers of the TT-genotype C825T of the GNB3 gene the body weight loss was higher than among the carriers of the C allele. 2. Changes in blood pressure and heart rate did not show any statistically significant relationship with polymorphisms of the TPH2 and GNB3 genes.

Download Full-text

A Meta-Analysis on Randomised Controlled Clinical Trials Evaluating the Effect of the Dietary Supplement Chitosan on Weight Loss, Lipid Parameters and Blood Pressure

Medicina ◽

10.3390/medicina54060109 ◽

2018 ◽

Vol 54 (6) ◽

pp. 109 ◽

Cited By ~ 5

Author(s):

Cristina Moraru ◽

Manuela Mincea ◽

Mirela Frandes ◽

Bogdan Timar ◽

Vasile Ostafe

Keyword(s):

Blood Pressure ◽

Weight Loss ◽

Clinical Trials ◽

Body Weight ◽

Dietary Supplement ◽

Serum Lipids ◽

Meta Analysis ◽

Density Lipoprotein ◽

The Body ◽

Obese Patients

Background and objectives: Erratic results have been published concerning the influence of the dietary supplement chitosan used as a complementary remedy to decrease the body weight of overweight and obese people. The published articles mention as secondary possible benefits of usage of chitosan the improvement of blood pressure and serum lipids status. We performed a meta-analysis evaluating body weight, body mass index, total cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol, triglycerides, systolic and diastolic blood pressure among overweight and obese patients. Materials and Methods: Searching MEDLINE, Cochrane up to December 2017 on clinical trials that have assessed the influence of chitosan used as a dietary supplement on overweight and obese patients. An additional study was identified in the References section of another meta-analysis. A total of 14 randomised control trials (RCT) were used to assess the effect on body weight, serum lipids and blood pressure. Results: The usage of chitosan as a dietary supplement up to 52 weeks seems to slightly reduce the body weight (−1.01 kg, 95% CI: −1.67 to −0.34). Considering the other parameters studied, the most significant improvement was observed in systolic and diastolic blood pressure: −2.68 mm Hg (95% CI: −4.19 to −1.18) and −2.14 mm Hg (95% CI: −4.14 to −0.14) in favour of chitosan versus a placebo. Conclusions: Based on the meta-analysis realized with 14 RCT we concluded that the usage of chitosan as a dietary supplement can lead to a slight short- and medium-term effect on weight loss and to the improvement of serum lipid profile and cardiovascular factors.

Download Full-text